评估前列地尔治疗糖尿病合并慢性肾脏病患者的效果和安全性

To evaluate the efficacy and safety of alprostadil in the treatment of diabetic patients with chronic kidney disease

目的:探讨前列地尔治疗糖尿病合并慢性肾脏病患者的临床效果和安全性。方法:选择2018年6月~2020年6月天津市公安医院收治的糖尿病合并慢性肾脏病患者120例按随机数字表法分为观察组和对照组各60例,对照组给予常规药物治疗,观察组给予前列地尔口服治疗,对比分析两组患者临床治疗效果、肾功能各指标及不良反应情况。结果:观察组患者治疗总有效率93.33%高于对照组患者的78.33%,差异有统计学意义(P<0.05)。治疗前两组肾功能指标相比,差异无统计学意义(P>0.05);治疗后观察组患者肾功能各指标均优于对照组患者,差异有统计学意义(P<0.05)。两组患者不良反应发生率相比,差异无统计学意义(P>0.05)。结论:前列地尔治疗糖尿病合并慢性肾脏病效果较佳,能够改善肾功能,且安全可靠。

Objective To explore the clinical efficacy and safety of alprostadil in the treatment of diabetic patients with chronic kidney disease.Method 120 patients with diabetes and chronic kidney disease were selected from June 2018 to June 2020,Divided into two groups according to the random number table method,60 cases in each group.The control group was given routine medication,The observation group was given alprostadil oral treatment.The clinical efficacy,renal function indexes and adverse reactions were compared and analyzed.Results The total effective rate of treatment in observation group was 93.33%,Which was higher than 78.33%of the control group,the difference was statistically significant(P<0.05);Before treatment,Compared with the two groups,The difference was not statistically significant(P>0.05);After treatment,the indexes of renal function in the observation group were better than those in the control group,the difference was statistically significant(P<0.05);Compared with the incidence of adverse reactions in the two groups,and the difference was not statistically significant(P>0.05).Conclusion Alprostadil is effective in treating diabetes with chronic kidney disease,Can improve kidney function,And safe and reliable.